{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:14:54Z","timestamp":1791519294045,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T00:00:00Z","timestamp":1380067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s11095-013-1181-6","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T01:35:07Z","timestamp":1380072907000},"page":"566-578","source":"Crossref","is-referenced-by-count":45,"title":["Preparation, Characterization, and Evaluation of Dipfluzine\u2013Benzoic Acid Co-crystals with Improved Physicochemical Properties"],"prefix":"10.1007","volume":"31","author":[{"given":"Yulong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,25]]},"reference":[{"issue":"7","key":"1181_CR1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.addr.2007.05.006","volume":"59","author":"DJ Hauss","year":"2007","unstructured":"Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667\u201376.","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"1181_CR2","first-page":"78","volume":"4","author":"RD Connors","year":"2004","unstructured":"Connors RD, Elder EJ. Using a portfolio of particle growth technologies to enable delivery of drugs with poor water solubility. Drug Deliv Technol. 2004;4(8):78\u201383.","journal-title":"Drug Deliv Technol"},{"issue":"1\u20132","key":"1181_CR3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2009.08.005","volume":"382","author":"W Limwikrant","year":"2009","unstructured":"Limwikrant W, Higashi K, Yamamoto K, Moribe K. Characterization of ofloxacin-oxalic acid complex by PXRD, NMR, and THz spectroscopy. Int J Pharm. 2009;382(1\u20132):50\u20135.","journal-title":"Int J Pharm"},{"issue":"1","key":"1181_CR4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jps.10468","volume":"93","author":"L Fand","year":"2004","unstructured":"Fand L, Numajiri S, Kobayashi D, Ueda H, Nakayama K, Miyamae H, et al. Physicochemical and crystallographic characterization of mefenamic acid complexes with alkanolamines. J Pharm Sci. 2004;93(1):144\u201354.","journal-title":"J Pharm Sci"},{"issue":"7","key":"1181_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.addr.2007.05.011","volume":"59","author":"N Blagden","year":"2007","unstructured":"Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59(7):617\u201330.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"1181_CR6","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/cg800173d","volume":"8","author":"MK Stanton","year":"2008","unstructured":"Stanton MK, Bak A. Physicochemical properties of pharmaceutical co-crystals: a case study of ten AMG 517 co-crystals. Cryst Growth Des. 2008;8(10):3856\u201362. doi: 10.1021\/cg800173d .","journal-title":"Cryst Growth Des"},{"issue":"6","key":"1181_CR7","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1021\/cg900129f","volume":"9","author":"N Schultheiss","year":"2009","unstructured":"Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9(6):2950\u201367.","journal-title":"Cryst Growth Des"},{"issue":"1","key":"1181_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2008.07.014","volume":"71","author":"J Aaltonen","year":"2009","unstructured":"Aaltonen J, Alles M, Mirza S, Koradia V, Gordon KC, Rantanen J. Solid form screening\u2013a review. Eur J Pharm Biopharm. 2009;71(1):23\u201337.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"1181_CR9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2008.04.043","volume":"364","author":"J Aaltonen","year":"2008","unstructured":"Aaltonen J, Gordon KC, Strachan CJ, Rades T. Perspectives in the use of spectroscopy to characterise pharmaceutical solids. Int J Pharm. 2008;364(2):159\u201369.","journal-title":"Int J Pharm"},{"issue":"2","key":"1181_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2116\/analsci.24.185","volume":"24","author":"Y Ueno","year":"2008","unstructured":"Ueno Y, Ajito K. Analytical terahertz spectroscopy. Anal Sci. 2008;24(2):185\u201392.","journal-title":"Anal Sci"},{"issue":"4","key":"1181_CR11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/jps.10358","volume":"92","author":"PF Taday","year":"2003","unstructured":"Taday PF, Bradley IV, Arnone DD, Pepper M. Using terahertz pulse spectroscopy to study the crystalline structure of a drug: a case study of the polymorphs of ranitidine hydrochloride. J Pharm Sci. 2003;92(4):831\u20138.","journal-title":"J Pharm Sci"},{"issue":"8","key":"1181_CR12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1248\/cpb.c12-00245","volume":"60","author":"D Li","year":"2012","unstructured":"Li D, Wang M, Yang CQ, Wang J, Ren GD. Solid state characterizations and analysis of stability in azelnidipine polymorphs. Chem Pharm Bull. 2012;60(8):995\u20131002.","journal-title":"Chem Pharm Bull"},{"issue":"7","key":"1181_CR13","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1039\/c2ce06359j","volume":"14","author":"CQ Yang","year":"2012","unstructured":"Yang CQ, Zhang ZW, Zeng YL, Wang J, Wang YL, Ma BQ. Structures and characterizations of m-nisoldipine polymorphs. CrystEngComm. 2012;14(7):2589\u201394.","journal-title":"CrystEngComm"},{"issue":"19","key":"1181_CR14","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1039\/c3ce26967a","volume":"15","author":"WG Lian","year":"2013","unstructured":"Lian WG, Lin YL, Wang M, Yang CQ, Wang J. Crystal engineering approach to produce complex of azelnidipine with maleic acid. CrystEngComm. 2013;15(19):3885\u201391.","journal-title":"CrystEngComm"},{"issue":"6","key":"1181_CR15","first-page":"448","volume":"20","author":"QF Miao","year":"2006","unstructured":"Miao QF, Su SW, Zhang W, Guo MF, Li LF, Meng J, et al. Effects of dipfluzine on experimental arrhythmias and cytosolic calcium concentration. Chin J Pharmacol Toxicol. 2006;20(6):448\u201354.","journal-title":"Chin J Pharmacol Toxicol"},{"issue":"10","key":"1181_CR16","first-page":"905","volume":"23","author":"C Wang","year":"2002","unstructured":"Wang C, Zhang YJ, Wang YL. Effects of dipfluzine on delayed afterdepolarizations and triggered activity induced by ouabain in guinea pig papillary muscles. Acta Pharmacol Sin. 2002;23(10):905\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"1181_CR17","first-page":"318","volume":"14","author":"YJ Zhang","year":"2000","unstructured":"Zhang YJ, Wang YL, He RR. Effect of dipfluzine on isop renaline induced early afterdepolarizations and triggered activity. Chin J Pharmacol Toxicol. 2000;14(4):318\u201320.","journal-title":"Chin J Pharmacol Toxicol"},{"key":"1181_CR18","unstructured":"Du YM, Wang YL, Zhang K, Gu JM. The synthesis methods of dipfluzine complex salts, Chinses patent CN101381349A; Mar 11, 2009."},{"issue":"9","key":"1181_CR19","first-page":"2476","volume":"31","author":"CQ Yang","year":"2011","unstructured":"Yang CQ, Wang J, Zhang ZW. Synthesis and spectra chatacteristic of pharmaceutical dipfluzine hydrochloride-benzoic acid co-crystal. Spectrosc Spectr Anal. 2011;31(9):2476\u20139.","journal-title":"Spectrosc Spectr Anal"},{"key":"1181_CR20","unstructured":"20 Wang YL, Chen ZM, Bao CH, Zhang YJ. The synthesis methods of dipfluzine, Chinses patent CN 1326845C; July 18, 2007"},{"key":"1181_CR21","unstructured":"Jin YH, Preparation and study of dipfluzine intragastric floating and residence sustained-release tablet. Master dissertation, Hebei Medical University. 2004"},{"issue":"6","key":"1181_CR22","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1021\/cg900129f","volume":"9","author":"N Schultheiss","year":"2009","unstructured":"Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9(6):2950\u201367.","journal-title":"Cryst Growth Des"},{"key":"1181_CR23","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1039\/b517118k","volume":"13","author":"CB Aaker\u00f6y","year":"2006","unstructured":"Aaker\u00f6y CB, Desper J, Scott BMT. Balancing supramolecular reagents for reliable formation of co-crystals. Chem Comm. 2006;13:1445\u20137.","journal-title":"Chem Comm."},{"issue":"3","key":"1181_CR24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1021\/cg049682i","volume":"5","author":"CB Aaker\u00f6y","year":"2005","unstructured":"Aaker\u00f6y CB, Desper J, Leonard B, Urbina JF. Toward high-yielding supramolecular synthesis: directed assembly of ditopic imidazoles\/benzimidazoles and dicarboxylic acids into cocrystals via selective O-H\u2009\u00b7\u2009\u00b7\u2009\u00b7\u2009N hydrogen bonds. Cryst Growth Des. 2005;5(3):865\u201373.","journal-title":"Cryst Growth Des"},{"issue":"3","key":"1181_CR25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/mp060126o","volume":"4","author":"CB Aaker\u00f6y","year":"2007","unstructured":"Aaker\u00f6y CB, Fasulo ME, Desper J. Cocrystal or salt: does it really matter? Mol Pharm. 2007;4(3):317\u201322.","journal-title":"Mol Pharm"},{"issue":"10","key":"1181_CR26","first-page":"o2719","volume":"E67","author":"J Wang","year":"2011","unstructured":"Wang J, Wang YL, Yang CQ. 1-Diphenylmethyl-4-[3-(4-fluorobenzoyl)propyl]piperazine-1,4-diium dichloride monohydrate. Acta Cryst. 2011;E67(10):o2719.","journal-title":"Acta Cryst"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-013-1181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-013-1181-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-013-1181-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T08:00:47Z","timestamp":1564041647000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-013-1181-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,25]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1007\/s11095-013-1181-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,25]]}}}